MRNA
Moderna, Inc. Common StockBiological Products, (No Diagnostic Substances)
$154.04updated Sep 19, 2026
Congressional trading profile for Moderna, Inc. Common Stock (MRNA), covering 7 disclosed transactions by 4 lawmakers.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Total Trades
7
Politicians Trading
4
Last Traded
Aug 24, 2026
Price history
Congressional Trades
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Maria Elvira SalazarR | Sep 9, 2026 | Aug 19, 2026 | Buy | $1,001 - $15,000 | -11.66% |
| Maria Elvira SalazarR | Sep 9, 2026 | Aug 19, 2026 | Sell | $1,001 - $15,000 | -11.66% |
| Ro KhannaD | Sep 4, 2026 | Aug 24, 2026 | Buy | $1,001 - $15,000 | +10.91% |
| Ro KhannaD | Sep 4, 2026 | Aug 3, 2026 | Sell | $1,001 - $15,000 | +179.36% |
| Robert BresnahanR | May 8, 2025 | Apr 8, 2025 | Sell | $1,001 - $15,000 | +525.16% |
| Robert BresnahanR | Mar 27, 2025 | Feb 25, 2025 | Buy | $1,001 - $15,000 | +362.86% |
| Julie JohnsonD | Feb 12, 2025 | Jan 15, 2025 | Sell | $1,001 - $15,000 | +343.03% |